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Background: Probably related to immune dysfunction, psoriasis vulgaris is a chronic, painful, disfiguring and
disabling dermatological disease, carrying an increased risk of serious comorbidities. Current conventional therapies
can be costly, show risks of side effects and have limited efficacy, with relapse common on treatment cessation.
Chinese herbal medicine is effective in treating psoriasis vulgaris. However, any benefit of adding Chinese herbal
medicine to conventional treatments when treating psoriasis vulgaris is yet to be determined.
Methods/design: This is a pilot randomized, placebo controlled, double-blinded trial. The pilot is primarily to
determine the feasibility of undertaking a full size randomized trial. Thirty participants with psoriasis vulgaris and
Psoriasis Area Severity Index (PASI) scores ≥7 and ≤12 will be included. Participants will be randomized (in a 1:1
ratio) to receive oral granulated Chinese herbal medicine YXBCM01 plus topical calcipotriol 0.005% or oral YXBCM01
placebo plus topical calcipotriol 0.005% treatment for 12 weeks, with a 12-week follow-up phase. The Chinese
herbal medicine or placebo will be administered orally as dissolvable granules. The primary outcome measure will
be PASI change (%) from baseline to the end of treatment phase. Secondary outcomes will include safety, key
psoriasis-related cytokine changes (for example, IL12, IL17 and IL 23) during the entire trial and symptom relapse
rates at the end of the follow-up phase.
Discussion: The study will evaluate the feasibility of a randomized controlled trial investigating combined
conventional and Chinese herbal medicine therapy for psoriasis vulgaris. The ingredients of YXBCM01 were selected
based on literature, the expert opinion on herbal medicine and pre-clinical evidence, for instance Chinese herbal
medicine possesses anti-inflammatory or antiproliferative properties.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12614000493640.
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Psoriasis is described by the World Health Organization
as a ‘chronic, non-communicable, painful, disfiguring and
disabling disease for which there is no cure’ [1]. The
pathogenesis of psoriasis is understood to be related to
immune system dysfunction, with increased function and
infiltration of immune cells such as lymphocytes and
hyperproliferation of keratinocytes, with consequent in-
flammatory changes [2]. Psoriasis vulgaris (or plaque type
psoriasis) is the most common type of psoriasis, making
up 90% of psoriatic cases [3]. Characterized by well-
defined, raised red patches (plaques) with adherent thick
silvery scales, psoriasis vulgaris is a relatively common der-
matological condition [3]. Psoriasis has the highest preva-
lence of any autoimmune diseases in the USA (between
3.1 and 5.1%) [4,5]. Related healthcare costs are estimated
at US $11.3 billion per annum, with further losses in prod-
uctivity calculated at around $16.5 billion per annum [6,7].
An Australian psoriasis prevalence study calculated an
even greater percentage with an estimated 6.6% of the
adult population affected [8].
Increased comorbidity risks linked to psoriasis include
cardiovascular disease, diabetes, cancer, hypertension,
obesity, depression and osteoporosis. Death from cardio-
vascular disease alone has been shown to be increased
by 57% in patients with psoriasis [9,10]. On average,
people with severe psoriasis die 5 years younger than
those without psoriasis [11]. Treatment guidelines rec-
ommend monitoring plaque severity, most commonly
utilizing the Psoriasis Area Severity Index (PASI) [12]. In
addition, quality-of-life estimation using a validated in-
strument, such as the Dermatology Life Quality Index, is
also recommended [13,14].
First-line therapies typically involve application of topical
drugs (such as corticosteroids and vitamin D analogues).
Second-line therapies consist commonly of ultraviolet light
therapy (UVB or UVA), classical systemic drugs, such as
methotrexate, retinoids and cyclosporine, or, more re-
cently, biologic drugs [15-17]. Systemic biologics, although
often effective, are used cautiously, owing to concerns
surrounding the safety profile for their long-term use
[6,18]. Associated costs of biologics can also be rela-
tively high [19].
Chinese herbal medicine has been used frequently for
symptoms associated with psoriasis. The use of Chinese
herbal medicine can be dated back to approximately
5000 years ago [20]. Clinically, to treat disease, Chinese
herbal medicines are combined into formulae for topical
or oral administration. Administered alone, or alongside
conventional therapies, both forms of Chinese herbal
medicine are clinically utilized to treat psoriasis vulgaris
[21]. Recently published clinical guidelines for Chinese
medicine recommend several different topical and oral
formulae, to be used for psoriasis. Published researchevidence evaluating the use of these medicines in psoria-
sis is, however, lacking [22,23]. Previous clinical trial evi-
dence indicates, when combining oral Chinese herbal
medicine with pharmaceutical drugs, that there may be
add-on effects that increase the overall effectiveness and
reduce pharmaceutical adverse effects. A previous sys-
tematic review suggests, however, that the results should
be interpreted cautiously, owing to methodological flaws
of reported studies [24]. A rigorously designed random-
ized controlled trial to investigate the add-on effects of
combining oral Chinese herbal medicine with conven-
tional pharmacotherapy for the treatment of psoriasis
vulgaris is warranted.
Chinese herbal medicine formula development
The composition of the Chinese herbal medicine formula
was determined based on previous clinical use, Chinese
herbal medicine expert consensus and identified com-
pounds of the ingredients that have antipsoriatic related
pathways (such as anti-inflammation and antiproliferation)
[25,26]. Similarly, the botanical components have multiple
Chinese herbal medicine functions that are likely to act on
the known psoriasis Chinese medicine syndromes of blood
heat, blood dryness or blood stasis. Radix Paeoniae Rubra
(chi shao) has Chinese medicine functions of clearing heat
and cooling blood whilst one of its key compounds, paeo-
niflorin, has shown to be a platelet aggregation inhibitor
[27]. Sarcandra glabra (jiu jie cha) has the Chinese medi-
cine function of reducing heat in the blood and contains
the compound fumaric acid, which is a known longstand-
ing treatment for psoriasis [28]. Rhizoma Smilacis Glabrae
(tu fu ling) has the Chinese medicine function of eliminat-
ing toxic heat and syringic acid, one of its components,
shows evidence of antibacterial action [29]. Other botani-
cals contained in YXBCM01 have the Chinese medicine
functions of invigorating blood circulation, harmonizing
other botanicals, tonifying Qi and removing heat from the
blood. Further potential biological actions of the key com-
ponents include: antineoplastic, immunosuppressive and
enhanced anti-inflammatory and antibacterial activity.
Methods/design
The study will investigate Chinese herbal medicine
YXBCM01 combined with conventional therapy (calci-
potriol) for psoriasis vulgaris in an Australian population
with PASI severity ≥7 and ≤12. The study was developed
in collaboration with a Chinese study also currently in-
vestigating YXBCM01 but combined with a different
conventional therapy (calcipotriol betamethasone), for
relapse rate in a Chinese population with psoriasis vul-
garis of greater severity [30]. The Australian study is de-
signed as a double-blind, randomized placebo controlled
trial to determine the feasibility of the trial protocol,
prior to undergoing a full scale trial. It will also provide
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bined YXBCM01 and calcipotriol, compared with calci-
potriol and placebo. The trial protocol was approved
by the RMIT University Human Research Ethics Com-
mittee, filed with the Therapeutic Goods Administration
under the Clinical Trial Notification scheme and regis-
tered with the Australian and New Zealand Clinical
Trials Registry, ACTRN12614000493640.
Trial procedure
The entire trial consists of an initial assessment, a two-
week run-in phase (week −2 and −1), a 12-week treatment
phase (week 1 to week 12) and a 12-week follow-up phase
(week 13 to week 24) (Figure 1).
Potential participants will be invited to an initial as-
sessment (first visit) consisting of inclusion and exclu-
sion criteria screening. If eligible, participants will be
asked for informed consent and undergo assessment of
PASI [31], body surface area [32], Dermatology Life
Quality Index [33] and Skindex 29 [34], as well as full
blood count, kidney and liver function blood tests. Par-
ticipants will then partake in a two-week run-in phase
(weeks −2 and −1). During this period, psoriasis-related
medication and herbal supplement use will be restricted.
Participants will be provided with a moisturizer (sorbo-
lene cream), to be applied as required during this period,
to ease symptom discomfort until the treatment phaseFigure 1 Trial procedure flowchart. CHM: Chinese herbal medicine.commences. After the run-in period, participants will
undergo baseline assessments (second visit), including
assessment of PASI, body surface area, Dermatology Life
Quality Index, Skindex 29, and Chinese medicine theory
of syndrome diagnosis (blood heat, blood dryness or
blood stasis) [35]. Photographs of a typical lesion area
will be taken, masking the identity of the participants;
these will then be coded and placed in the participants’
case report forms [28].
After baseline assessments, participants will be ran-
domized to receive 12 weeks of YXBCM01 plus calcipo-
triol, or placebo YXBCM01 plus calcipotriol treatment.
During the treatment phase, psoriasis symptom mea-
sures will be self-reported by participants and recorded
in a daily or weekly diary. Face-to-face assessments with
blinded assessors will be scheduled at weeks 6 (third
visit) and 12 (fourth visit), with further data collected in-
cluding symptom severity, safety, trial drug usage,
physiological tests and lesion photos (Table 1). Phone
calls will be made to participants at weeks 2, 4, 8 and 10
to check adherence to the dosage guidelines and moni-
tor adverse events.
Participants will record any reductions in calcipotriol
dosage along with reasoning, in a daily diary. The
YXBCM01 therapy and placebo initial dosages will be
continued till the end of the 12-week treatment phase,
regardless of psoriatic lesion clearance. Any unused trial























Pre-assessment (Visit 1, Week −2) × × × × × ×
Baseline assessment (Visit 2, Week 1) × × × × × ×
Daily or weekly self-assessment during
8 weeks treatment (Weeks 1 to 12)
× ×
Compliance assessment phone call
(Weeks 2 and 4)
× ×
Mid-treatment assessment (Visit 3, Week 6) × × × × × × (liver and kidney
function only)
× ×
Compliance assessment phone call (Week
8 and 10)
× ×
End of treatment assessment (Visit 4, Week 12) × × × × × × × × × ×
Daily or weekly self-assessment during 12 weeks
follow-up (weeks 13 to 24)
× ×
End of follow-up assessment (Visit 5 or Week 24) × × × × × × × × × ×
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sessment and measured to assess compliance.
For the 12-week follow-up phase, participants will con-
tinue to record symptoms in their daily or weekly diaries
and document their utilization of health resources (includ-
ing drug therapy use). At week 24 participants, will attend
an end of follow-up assessment (fifth visit); following this,
the participants’ involvement in the trial will cease.
Setting and participants
The study will be undertaken at the clinical trial facilities
of the Research Hub of the School of Health Sciences,
RMIT University, in Melbourne, Australia. Recruitment
will be through poster advertisement, newspaper adver-
tisement, newsletters and Internet advertisement. Partic-
ipants might also be invited to contact trial coordinators
by their treating physician (general practitioner, derma-
tologist or immunologist). Thirty participants will be in-
cluded in the study after providing written informed
consent. The selection criteria are as follows.
Inclusion criteria
Participants will be included only if they satisfy the fol-
lowing: (1) aged between 18 and 70 years; (2) at least a
12-month history of psoriasis vulgaris symptoms diag-
nosed by a physician and where calcipotriol would be
appropriate treatment; (3) PASI score ≥7 and ≤12; (4) in-
formed consent is provided.
Exclusion criteria
People with any of the following will be excluded from
participation: (1) pregnant or breast-feeding; (2) psoriasis
type is not vulgaris; (3) taking systemic drugs or photo-
therapy for psoriasis within 4 weeks prior to screening; (4)
taking topical drug treatment for psoriasis within 2 weeks
prior to screening; (5) other severe disorders; (6) known
disorders of calcium metabolism (high blood calcium
levels); (7) known kidney function disorders; (8) taking cal-
cium, vitamin D supplements or vitamin D-like medicines;
(9) known sensitivity to Chinese herbs; (10) known sensi-
tivity to calcipotriol; (11) unwilling or unable to cease
other topical or systemic psoriasis-related medication for
duration of the trial.
Interventions
Chinese herbal medicine
The oral Chinese herbal medicine granule (named
YXBCM01) will be produced by a manufacturer holding
a Good Manufacturing Practice certificate.
Developed by a renowned Chinese herbal medicine clin-
ician (Professor Guowei Xuan), YXBCM01 includes Radix
Paeoniae Rubra (chi shao), Sarcandra glabra (jiu jie cha),
Rhizoma Smilacis Glabrae (tu fu ling). A previous obser-
vational study of YXBCM01 for psoriasis vulgaris showeda reduction in PASI and Dermatology Life Quality Index
score with no significant adverse events [36]. The formula-
tion is registered with the Guangdong Food and Drug Ad-
ministration (hospital preparation approval number
Z20080123). The botanicals will be mixed, cooked, filtered
and pressure spray-dried, forming granules. These will be
packaged in small single-dose sachets (9.5 cm× 6.0 cm),
weighing 5.5 g each. The intervention group will receive
individually packaged doses (n = 168) of YXBCM01, with
each dose to be dissolved in warm water and consumed
orally twice daily for 12 weeks.
Placebo
Placebo will be produced by the same manufacturer as
the YXBCM01 granules and consist of starch with no ac-
tive ingredients. It will be matched as closely as possible
to the appearance and taste of the YXBCM01 granules.
The colour will be made identical by adding artificial
pigment whilst the taste will be adjusted by adding a
medicine intermediate.
Dosage and administration instructions for the YXBCM01
and placebo groups will be identical.
Pharmacotherapy
The topical drug calcipotriol 0.005% (50 μg/g) cream
(30 g tubes) will be administered as standard care. Calci-
potriol is a vitamin D3 derivative, which decreases prolif-
eration and induces the differentiation of keratinocytes.
It has a strong immunomodulating effect, reducing
the level of pro-inflammatory cytokines [37,38]. It is a
moderate-action first-line therapy drug, with a low risk
of side effects and proven efficacy; it is commonly used
and treatment guidelines recommend it for mild to
moderate psoriasis [39]. The calcipotriol cream will be
administered daily, for 12 weeks, to affected body sur-
face areas according to American Academy of Dermatol-
ogy guidelines (1% surface area coverage = 0.5 fingertip
units), or until the complete clearance of lesions [15].
The maximum dose will not exceed 100 g per week, ac-
cording to consumer medicine information for the prod-
uct (calcipotriol). The calcipotriol dosage can be reduced
from its initial dose at the participants’ discretion and as
their symptoms reduce, but should meet dosage recom-
mendations for the severity of the plaques. In addition,
in case of intolerable itch, antihistamine (cetirizine
hydrochloride tablets 10 mg) will be provided to all par-
ticipant groups as rescue therapy.
Objectives
The objectives of this randomized controlled trial are:
 To investigate any add-on benefit of oral Chinese
herbal medicine (YXBCM01) to calcipotriol for the
management of psoriasis vulgaris;
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herbal medicine (YXBCM01) and calcipotriol is safe
for the management of psoriasis vulgaris.
Outcome measures
Primary outcome measures
The primary outcome measure will be PASI change (%
mean) from baseline to end of treatment (week 12) and
end of follow-up phase (week 24) (see Table 1).
Secondary outcome measures
 PASI 75 (proportion (%) of participants achieving a
PASI improvement of 75%) (week 12);
 PASI 50 (proportion (%) of participants achieving a
PASI improvement of 50%) (week 12);
 Relapse rate (return of lesion to 50% of baseline
PASI score [40]) (week 24);
 Change in body surface area (%) (week 12);
 Change in Dermatology Life Quality Index score (%)
(week 12);
 Skindex 29 score change (%) (week 12);
 Acceptability and willingness to repeat treatment
(week 12);
 Blood test (full blood, kidney and liver function
tests) (weeks 6, 12 and 24);
 Body mass index change (%) (week 12);
 Reported adverse events and serious adverse events;
 Health resource utilization data (medical doctor
visits, hospital visits and medication usage).
Acceptability will be measured on an ordinal scale from
0 to 10, where 0 equals very dissatisfied with the treatment
and 10 equals very satisfied with the treatment. Willing-
ness to repeat the treatment will be measured on a Likert
scale (definitely not, probably not, probably yes, definitely
yes or unsure) (week 12). Any adverse events will be re-
corded by the participant and assessed by blinded asses-
sors at each assessment period.
A full blood count test, as well as liver and kidney func-
tion tests, will be completed at weeks −2, 6, 12 and 24
(Table 1). These will measure the impact of the interven-
tions on blood inflammatory markers, as well as monitor-
ing toxicology safety for significant changes in kidney and
liver function. Samples of serum will be collected and
stored for further investigation of changes to the concen-
tration of key cytokines (weeks −2, 12 and 24). Adverse
events will be recorded from participants’ reports and as-
sessors’ observations, then classified as probably related to
either Chinese herbal medicine or pharmacotherapy. Any
serious adverse event will be reported to RMIT University
Human Research Ethics Committee, a data safety and
monitoring board and the Therapeutic Goods Administra-
tion of Australia. Health resource utilization data will becollected in case report forms; data will include number
and reason of hospitalizations, number of medical doctor
related visits, reason for visit and use of medication related
to psoriasis (frequency and dosage).
Potential adverse events
Potential adverse events of calcipotriol are considered
minor and may consist of minor skin irritation (including
peeling or rash), change in skin colour or skin sensitivity
to light [41]. For the YXBCM01, the herbal constitu-
ents are commonly used clinically. Minor side effects of
YXBCM01 are possible but are not specific to the investi-
gated herbal substances; although uncommon, they may
consist of nausea or diarrhoea [42]. If participants develop
adverse events or if the results of their blood tests for liver
and kidney function become abnormal, participants will
be advised to stop all trial-related medication and seek
medical advice from their doctors as to their safe continu-
ation in the study.
Termination and withdrawal
A data safety and monitoring board of independent ex-
perts in pharmacological studies, dermatology and statis-
tics has been formed. The data safety and monitoring
board will review and evaluate the study data for safety
and study conduct, to make recommendations regard-
ing the continuation, modification or termination of the
study. Serious adverse events will be judged according to
Therapeutic Goods Administration criteria (2006): ‘Any
untoward medical occurrence that at any dose: results in
death, is life-threatening, requires inpatient hospitalization
or prolongation of existing hospitalization, results in per-
sistent or significant disability/incapacity, is a congenital
anomaly or birth defect, or is a medically important
event or reaction’ [43]. If judgement is made by the
relevant human research ethics committee, Therapeutic
Goods Administration, data safety and monitoring
board or study investigators that participants are at ser-
ious risk as a result of serious adverse event reported
in the study, the study will be terminated. In addition,
participants are permitted to withdraw at any time
throughout the duration of the trial, with or without
reason. All withdrawn participants who have received
the intervention will be followed-up 8 weeks post with-
drawal, to obtain information regarding their condition
and any subsequent adverse events.
Sample size determination
A pilot study of 30 participants testing the feasibility of
the trial protocol will be conducted prior to a full scale
trial. Post-hoc power analysis via effect size estimation
on the pilot study data will be used to determine sample
size for a full scale trial.
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concealment
Participants will be randomly allocated to intervention
(YXBCM01 plus calcipotriol) or control group (placebo plus
calcipotriol) in equal ratio (1:1). Randomization numbers
will be computer generated in blocks and corresponding
codes sealed in opaque envelopes. Envelopes will be opened
sequentially from each block only after the participant’s de-
tails are written on the outside of the envelope. The code in-
side the envelope will correspond to a package number that
will contain 12 weeks supply of either YXBCM01 granules
or identically packaged placebo granules.
Blinding
Participants, researchers and outcome assessors will be
blind to group allocation. Packaging and labelling of
study drugs will be conducted by persons independent
of the research team. The randomization sequence will
be sealed and stored in a locked filing cabinet, separate
from participants’ data and only accessible to persons
who generated the sequence. Testing of adequate par-
ticipant blinding will be undertaken at weeks 6, 12 and
24; participants will be asked whether they believe they
were given placebo, Chinese herbal medicine or are un-
sure. Randomization codes will only be broken after data
validation and entering processes are complete, or at the
request of the human research ethics committee, Thera-
peutic Goods Administration or the participant’s own
physician, if there is identified risk to a participant’s con-
tinuation in the study.
Data collection
Data will be collected and recorded in the case report
forms from participants via face-to-face and telephone
interviews or assessments. Participants will record fur-
ther daily and weekly data in a home data diary, to be
collected by researchers at subsequent assessment or re-
view appointments.
All data will be entered into a pre-designed, password-
protected dataset by personnel blinded to group allocation.
Data entry will be performed continuously throughout the
study using the double-check method, with any correc-
tion or changes of written data in participants’ case report
forms documented and dated.
Statistical analysis methods
All data will be analyzed by an independent statistician.
The Statistical Package for the Social Sciences software
version 21.0 for Windows (SPSS Inc., Armonk, New York,
USA) will be used for data analysis. Baseline demographic
characteristics on categorical variables, such as sex, will be
assessed for balance between the two treatment groups via
the chi square test, whilst continuous or interval variables
will be assessed for equivalence between the treatmentgroups by t tests. Intention-to-treat analysis will be applied
to outcome data to minimize bias due to withdrawals; all
missing data will be replaced using the last observation
carried forward. Continuous data will be presented as
means and standard deviation, or 95% confidence interval.
All dichotomous data, such as the percentage of partici-
pants achieving PASI 75, will be presented as risk ratio
and 95% confidence interval. Other outcomes (for ex-
ample, severity and quality of life) will be assessed for
equivalence in the two groups; P < 0.05 obtained from stat-
istical tests on variables involving treatment group com-
parisons will be considered statistically significant.
Discussion
Outcome measures used in this study
From research, complete clearance of psoriasis symptoms is
rarely achievable; as a result, treatment success is based on
reduction in PASI of 75% (PASI 75) [44]. Treatment failure
is regarded as a reduction in PASI of less than 50% (PASI
50). For those PASI changes falling between this range
(≥50% but <75%), the Dermatology Life Quality Index is
used to determine whether current treatment should be
modified or continue [45]. The Therapeutic Goods Admin-
istration recommends standard outcomes of PASI 75, PASI
50 and body surface area to assess product efficacy for psor-
iasis [44]. The Dermatology Life Quality Index is recom-
mended by both the Therapeutic Goods Administration
and the Australian College of Dermatologists, to evaluate
psoriasis severity and patients’ quality of life [12,44]. It is a
validated instrument that is well-recognized in psoriasis re-
search. The Skindex 29 has been evidenced for psoriasis as
the most sensitive scale, with high applicability; previous
evaluation identifies it as the most validated quality-of-life
instrument for dermatological conditions [46,47].
Chinese medicine syndrome approach
As yet, there is no conclusive evidence that utilizing
Chinese medicine syndrome theory in clinical trial treat-
ment will improve the efficacy of treatment [48]. Whilst
this study will not allocate treatment based on syndrome
differentiation, it will be able to analyze the results of
the intervention and investigate whether there are differ-
ences in efficacy between participants in each syndrome
group (blood heat, blood dryness or blood stasis). With
text books differing, there is conjecture about the num-
ber of Chinese medicine syndrome types for psoriasis;
the development of the Chinese medicine syndrome dif-
ferentiation criteria for this study was based on available
Chinese guidelines, as well as expert consensus [23].
Trial status
The trial is currently recruiting, following the protocol
stipulated in the Australian and New Zealand Clinical
Trials Registry.
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